fluorouracil has been researched along with Menopause in 234 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have investigated the relationship between c-erbB(2) status, estrogen receptor (ER) status and outcome in 274 women with node-positive breast cancer who, following excision and axillary clearance, were randomized to receive either 6 cycles of cyclophosphamide/methotrexate/fluorouracil (CMF) (n = 129) or no such treatment (n = 145)." | 9.09 | Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. ( Barnes, DM; Gillett, CE; Harris, WH; Miles, DW; Smith, P, 1999) |
| "To evaluate the effect of previous adjuvant chemotherapy with or without anthracyclines on overall survival (OS), progression-free survival (PFS), and objective response (OR) rates of metastatic breast cancer patients treated with cyclophosphamide, epidoxorubicin, and fluorouracil (CEF) as first-line chemotherapy." | 9.08 | Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. ( Bertelli, G; Bruzzi, P; Del Mastro, L; Garrone, O; Guelfi, M; Pastorino, S; Rosso, R; Sertoli, MR; Venturini, M, 1996) |
| "To compare two adjuvant combination chemotherapies, cyclophosphamide, methotrexate, and fluorouracil (CMF) and chlorambucil, methotrexate, and fluorouracil (LMF), for patients who had undergone potentially curative surgery for unilateral breast cancer, in terms of relapse, survival, and toxicity." | 9.08 | Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. ( Castiglione, M; Cavalli, F; Jungi, WF; Leyvraz, S; Maibach, R; Obrecht, JP; Schildknecht, O; Senn, HJ; Siegenthaler, P, 1997) |
| " We conducted a Phase II trial of an anthracycline analogue, pirarubicin, administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer." | 9.08 | Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ( Buzdar, A; Dhingra, K; Fraschini, G; Frye, D; Hortobagyi, GN; Newman, RA; Smith, T; Theriault, R; Walters, R, 1995) |
| "504 evaluable node positive oestrogen receptor (ER) positive breast cancer patients were randomly allocated to receive either 5 years tamoxifen treatment or chemotherapy [six courses of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 4 courses of epirubicin] or a combination of both treatments." | 9.07 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. ( Amoroso, D; Boccardo, F; Castagnetta, L; Farris, A; Genta, F; Nenci, I; Piffanelli, A; Rubagotti, A; Sismondi, P; Traina, A, 1992) |
| "To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes." | 9.07 | Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991) |
| "Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer." | 9.07 | A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. ( Ashley, S; Jodrell, DI; Mansi, JL; McKinna, JA; Pearson, MC; Sinnett, HD; Smith, IE; Walsh, G, 1991) |
| "A prospectively controlled randomized trial to compare the adjuvant efficacy of 12 cycles of cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen (CMFPT) followed by observation or a total of 5 years of continuous tamoxifen versus four cycles of CMFPT followed by observation in postmenopausal women with operable node-positive breast cancer was started by the Eastern Cooperative Oncology Group (ECOG) in 1982." | 9.06 | Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. ( Falkson, G; Falkson, HC; Gillchrist, KW; Gray, R; Harris, JE; Tormey, DC; Wolberg, WH, 1990) |
| "Between November 1, 1983 and June 30, 1987, 510 node-positive, estrogen receptor (ER)-positive breast cancer patients have been randomly allocated to receive either chemotherapy (six intravenous [IV] cyclophosphamide, methotrexate, and fluorouracil [CMF] courses followed by four IV epirubicin courses) or 5 years of tamoxifen treatment or a combination of both therapies." | 9.06 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. ( Boccardo, F; Bruzzi, P; Cappellini, M; Isola, G; Nenci, I; Piffanelli, A; Rubagotti, A; Santi, L; Scanni, A; Sismondi, P, 1990) |
| "Between 1976 and 1985, 391 patients (202 premenopausal, 189 postmenopausal) with operable breast cancer and positive axillary lymph nodes were randomized after total mastectomy and axillary clearance to receive cyclophosphamide, methotrexate, and fluorouracil (CMF) (n = 193) or no adjuvant therapy (n = 198)." | 9.06 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. ( Chaudary, MA; Crowther, D; Fentiman, IS; George, WD; Howell, A; O'Reilly, SM; Richards, MA; Rubens, RD, 1990) |
| "The efficacy and toxicity of leucovorin 500 mg/m2 administered intravenously (IV) over 30 minutes daily for five days followed in one hour by fluorouracil (5-FU) 375 mg/m2 administered IV daily for five days, each given every 3 weeks, was assessed in 54 previously treated patients with metastatic breast cancer." | 9.06 | Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. ( Allegra, CJ; Drake, JC; Egan, EF; Lippman, ME; Steinberg, SM; Swain, SM, 1989) |
| "Treatment with tamoxifen (TM), alone or in combination with cyclophosphamide, methotrexate, and fluorouracil (CMF), was used as an adjuvant to surgery in 433 patients with stage I, II, or III(T3a) breast cancer." | 9.06 | Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. ( Bianco, AR; D'Istria, M; De Placido, S; Delrio, G; Gallo, C; Marinelli, A; Pagliarulo, C; Petrella, G, 1988) |
| "The present paper concerns two multicenter studies on adjuvant therapy with medroxyprogesterone acetate (MAP) for operable N+ breast cancer." | 9.06 | Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. ( Camaggi, CM; Cilenti, G; Fruet, F; Martoni, A; Pannuti, F, 1988) |
| "Following mastectomy for node-positive breast cancer, 261 postmenopausal women were randomized to observation or adjuvant treatment with cyclophosphamide, fluorouracil, prednisone (CFP) alone or combined with tamoxifen (T)." | 9.06 | Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. ( Cullinan, SA; Everson, LK; Ingle, JN; Krook, JE; Martin, JK; Paulsen, JK; Twito, DI; Votava, HJ; Wieand, HS; Wold, LE, 1988) |
| "Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval." | 9.05 | Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984) |
| "Eighty-eight postmenopausal women with metastatic breast cancer, in whom estrogen receptors (ER) were positive or unknown, were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders." | 9.05 | Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer. ( Brodovsky, H; Catalano, RB; Creech, RH; Glick, JH; Holroyde, C; Torri, S; Varano, M, 1981) |
| "During the past 4 years, a sequential study was conducted to compare the effect of tamoxifen (TAM) alone and TAM plus 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) in the treatment of advanced breast cancer." | 9.05 | Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial. ( Koyama, H; Terasawa, T; Wada, T, 1981) |
| "Eighty-nine postmenopausal women with metastatic breast cancer, in whom estrogen receptors (ER) were positive or unknown, were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders." | 9.05 | Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial. ( Brodovsky, H; Catalano, RB; Creech, RH; Glick, JH; Holroyde, C; Torri, S; Varano, M, 1980) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 9.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 9.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| "In this study 263 patients with advanced measurable breast cancer were randomized to receive cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or CMF + tamoxifen (T)." | 9.05 | Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. ( Engelsman, E; Mouridsen, HT; Rose, C; Rotmensz, N; Sylvester, R, 1985) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 9.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "Eighty-one patients with advanced measurable breast cancer were randomized to receive only chemotherapy (Group C) or the same chemotherapy + tamoxifen (Group CH)." | 9.05 | Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study. ( Boccardo, F; Rosso, R; Rubagotti, A; Santi, L, 1985) |
| "Two hundred and sixty-three patients with advanced measurable breast cancer were randomized to receive cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or CMF + tamoxifen (T)." | 9.05 | Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen. ( Engelsmann, E; Mouridsen, HT; Rose, C; Rotmensz, N; Sylvester, R, 1985) |
| "Between November 1, 1976 and December 31, 1981, 826 post-menopausal females with operable breast cancer were included into a trial comparing tamoxifen 40 mg daily for 2 years with no endocrine treatment." | 9.05 | Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer. ( Baral, E; Glas, U; Karnström, L; Nordenskiöld, B; Silfverswärd, C; Theve, NO; Wallgren, A, 1985) |
| "The addition of levamisole, administered in adjunctive manner between the cycles of conventional high dose chemotherapy in patients with hormone resistant end state breast cancer substantially improved the survival of treated patients." | 9.04 | Levamisole: as adjuvant to cyclic chemotherapy in breast cancer. ( Mason, B; Stephens, EJ; Wood, HF, 1978) |
| "The effect of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or tamoxifen treatment on endocrine function was investigated in premenopausal and postmenopausal breast cancer patients." | 7.68 | Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen. ( Balar, DB; Bhatavdekar, JM; Ghosh, N; Giri, DD; Karelia, NH; Patel, DD; Shah, NG; Trivedi, SN; Vora, HH, 1992) |
| "Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement." | 7.67 | Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment. ( Bezwoda, WR; Browde, S; Derman, DP; Goss, G; Lange, M, 1984) |
| "A phase II trial in postmenopausal women with advanced breast cancer naive to cytotoxic treatment for recurrent disease was performed with a combinated chemo-endocrine regimen of prednimustine, methotrexate, mitoxantrone, 5-fluorouracil, and tamoxifen." | 7.67 | Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial. ( Andersson, M; Mouridsen, HT, 1988) |
| "The effect of adjuvant CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) and tamoxifen (TM) on hypothalamic-pituitary-ovarian function was studied in 120 women with stage I-II operable breast cancer." | 7.67 | Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. ( Citarella, F; Contegiacomo, A; d'Istria, M; De Placido, S; De Sio, L; Delrio, G; Fasano, S; Iaffaioli, RV; Marinelli, A; Pagliarulo, C, 1986) |
| "One hundred twenty-four patients with metastatic breast cancer were treated with 40 mg of megestrol acetate four times daily." | 7.67 | Megestrol acetate therapy for advanced breast cancer. ( Cohen, SC; Gregory, EJ; Mims, CH; Oines, DW, 1985) |
| "The effect of adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and tamoxifen (TM) on endocrine function was studied in 120 women with stage I-II operable breast cancer." | 7.67 | Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer. ( Bianco, AR; D'Istria, M; De Placido, S; De Sio, L; Delrio, G; Fasano, S; Pagliarulo, C; Ricciardi, I, 1985) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "Forty-seven patients with advanced breast cancer were treated with a combination of prednimustine (P), methotrexate (M), 5-fluorouracil (F), and tamoxifen (TAM)." | 7.66 | Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study. ( Boesen, E; Mouridsen, HT, 1983) |
| "One hundred and five patients with metastatic breast cancer were treated with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG (FAC-BCG)." | 7.66 | Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Einhorn, L; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Richman, SP; Tashima, CK, 1979) |
| "Weight gain is a common side effect observed in women undergoing adjuvant chemotherapy for breast cancer." | 6.70 | Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition. ( Banzi, MC; Bertolini, M; Bondi, M; Del Rio, G; Federico, M; Menozzi, R; Piccinini, L; Valeriani, L; Zironi, S, 2002) |
| "Amonafide is a new imide derivative of naphthalic acid." | 6.68 | Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). ( Berkowitz, I; Berry, D; Costanza, ME; Duggan, D; Henderson, IC; Kalra, J; Lyss, AP; Ratain, MJ; Shapiro, C; Wu, K, 1995) |
| "International Breast Cancer Study Group Trial VIII compared cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for 6 cycles followed by endocrine therapy with goserelin with either modality alone in pre- and perimenopausal patients." | 5.13 | Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. ( Braye, S; Brown, RW; Castiglione-Gertsch, M; Coates, AS; Gelber, RD; Goldhirsch, A; Golouh, R; Grigolato, P; Gusterson, BA; Kovács, A; Maiorano, E; Mastropasqua, MG; Ohlschlegel, C; Perin, T; Pillay, K; Price, KN; Regan, MM; Rusca, T; Viale, G, 2008) |
| "According to the overview of Early Breast Cancer Trialists' Collaborative Group, anthracycline containing regimens are superior to cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant chemotherapy for breast carcinoma, but no comparative information is available in terms of primary chemotherapy." | 5.10 | Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. ( Bella, M; Bisagni, G; Boni, C; Bruzzi, P; Camisa, R; Ceci, G; Cocconi, G; Di Blasio, B; Leonardi, F; Rondini, E; Savoldi, L, 2002) |
| "Cyclophosphamide, methotrexate and fluorouracil adjuvant combination chemotherapy for breast cancer is currently used for the duration of six monthly courses." | 5.10 | Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. ( Bastert, G; Beyerle, C; Bonetti, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Gelber, RD; Goldhirsch, A; Holmberg, SB; Lindtner, J; Litman, HJ; Neumann, RL; Rudenstam, CM; Sauerbrei, W; Schmoor, C; Schumacher, M; Thürlimann, B, 2002) |
| "We have investigated the relationship between c-erbB(2) status, estrogen receptor (ER) status and outcome in 274 women with node-positive breast cancer who, following excision and axillary clearance, were randomized to receive either 6 cycles of cyclophosphamide/methotrexate/fluorouracil (CMF) (n = 129) or no such treatment (n = 145)." | 5.09 | Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. ( Barnes, DM; Gillett, CE; Harris, WH; Miles, DW; Smith, P, 1999) |
| "Sixty-four consecutive patients with locally advanced (n = 7) or metastatic breast cancer (n = 57), were treated with a combination of laevofolinic acid 100 mg m-2 plus 5-fluorouracil 340 mg m-2 i." | 5.08 | Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM ( Agostara, B; Cariello, S; Colucci, G; Durini, E; Gebbia, V; Giotta, F; Pacilio, G; Pezzella, G; Romito, S; Testa, A, 1995) |
| "To evaluate the effect of previous adjuvant chemotherapy with or without anthracyclines on overall survival (OS), progression-free survival (PFS), and objective response (OR) rates of metastatic breast cancer patients treated with cyclophosphamide, epidoxorubicin, and fluorouracil (CEF) as first-line chemotherapy." | 5.08 | Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. ( Bertelli, G; Bruzzi, P; Del Mastro, L; Garrone, O; Guelfi, M; Pastorino, S; Rosso, R; Sertoli, MR; Venturini, M, 1996) |
| "To compare two adjuvant combination chemotherapies, cyclophosphamide, methotrexate, and fluorouracil (CMF) and chlorambucil, methotrexate, and fluorouracil (LMF), for patients who had undergone potentially curative surgery for unilateral breast cancer, in terms of relapse, survival, and toxicity." | 5.08 | Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. ( Castiglione, M; Cavalli, F; Jungi, WF; Leyvraz, S; Maibach, R; Obrecht, JP; Schildknecht, O; Senn, HJ; Siegenthaler, P, 1997) |
| " We conducted a Phase II trial of an anthracycline analogue, pirarubicin, administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer." | 5.08 | Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ( Buzdar, A; Dhingra, K; Fraschini, G; Frye, D; Hortobagyi, GN; Newman, RA; Smith, T; Theriault, R; Walters, R, 1995) |
| "504 evaluable node positive oestrogen receptor (ER) positive breast cancer patients were randomly allocated to receive either 5 years tamoxifen treatment or chemotherapy [six courses of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 4 courses of epirubicin] or a combination of both treatments." | 5.07 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. ( Amoroso, D; Boccardo, F; Castagnetta, L; Farris, A; Genta, F; Nenci, I; Piffanelli, A; Rubagotti, A; Sismondi, P; Traina, A, 1992) |
| "To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes." | 5.07 | Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991) |
| "Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer." | 5.07 | A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. ( Ashley, S; Jodrell, DI; Mansi, JL; McKinna, JA; Pearson, MC; Sinnett, HD; Smith, IE; Walsh, G, 1991) |
| "The influence of S-phase fraction (SPF), measured by DNA flow cytometry, and histological grade on outcome following adjuvant chemotherapy was analysed for 214 patients with node positive breast cancer treated at Guy's Hospital who were entered into the Guy's/Manchester trial of combination chemotherapy with cyclophosphamide/methotrexate/5-fluorouracil (CMF) vs." | 5.06 | Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. ( Camplejohn, RS; Millis, RR; O'Reilly, SM; Richards, MA; Rubens, RD, 1990) |
| "A prospectively controlled randomized trial to compare the adjuvant efficacy of 12 cycles of cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen (CMFPT) followed by observation or a total of 5 years of continuous tamoxifen versus four cycles of CMFPT followed by observation in postmenopausal women with operable node-positive breast cancer was started by the Eastern Cooperative Oncology Group (ECOG) in 1982." | 5.06 | Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. ( Falkson, G; Falkson, HC; Gillchrist, KW; Gray, R; Harris, JE; Tormey, DC; Wolberg, WH, 1990) |
| "Between November 1, 1983 and June 30, 1987, 510 node-positive, estrogen receptor (ER)-positive breast cancer patients have been randomly allocated to receive either chemotherapy (six intravenous [IV] cyclophosphamide, methotrexate, and fluorouracil [CMF] courses followed by four IV epirubicin courses) or 5 years of tamoxifen treatment or a combination of both therapies." | 5.06 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. ( Boccardo, F; Bruzzi, P; Cappellini, M; Isola, G; Nenci, I; Piffanelli, A; Rubagotti, A; Santi, L; Scanni, A; Sismondi, P, 1990) |
| "Between 1976 and 1985, 391 patients (202 premenopausal, 189 postmenopausal) with operable breast cancer and positive axillary lymph nodes were randomized after total mastectomy and axillary clearance to receive cyclophosphamide, methotrexate, and fluorouracil (CMF) (n = 193) or no adjuvant therapy (n = 198)." | 5.06 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. ( Chaudary, MA; Crowther, D; Fentiman, IS; George, WD; Howell, A; O'Reilly, SM; Richards, MA; Rubens, RD, 1990) |
| "The Eastern Cooperative Oncology Group (ECOG) trial of adjuvant cyclophosphamide, methotrexate, fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen (CMFPT) for 1 year compared with observation alone in 265 postmenopausal patients with node-positive breast cancer is reported with 74 months median follow-up." | 5.06 | Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Gilchrist, KW; Knuiman, MW; Olson, JE; Rosenthal, SN; Sleeper, LA; Taylor, SG; Tormey, DC, 1989) |
| "The efficacy and toxicity of leucovorin 500 mg/m2 administered intravenously (IV) over 30 minutes daily for five days followed in one hour by fluorouracil (5-FU) 375 mg/m2 administered IV daily for five days, each given every 3 weeks, was assessed in 54 previously treated patients with metastatic breast cancer." | 5.06 | Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. ( Allegra, CJ; Drake, JC; Egan, EF; Lippman, ME; Steinberg, SM; Swain, SM, 1989) |
| "Postmenopausal women who underwent modified radical mastectomy for Stage II, estrogen receptor (ER)-positive breast cancer were randomized to receive endocrine treatment (tamoxifen [T], 40 mg daily for 3 years) alone versus endocrine treatment plus five-drug chemotherapy (Cytoxan [cyclophosphamide, C], methotrexate [M], 5-fluorouracil [F], vincristine [V], and prednisone [P], CMFVP, for 1 year)." | 5.06 | Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. ( Arafah, BM; Crowe, JP; Gordon, NH; Hubay, CA; Marshall, JS; McGuire, W; Pearson, OH, 1989) |
| "The relation between tumour oestrogen and progesterone receptor status, menstrual status, relapse-free survival, and overall survival was analysed in 411 patients with early breast cancer randomised to receive either postoperative adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) or no additional treatment (control)." | 5.06 | Mechanism of action of adjuvant chemotherapy in early breast cancer. ( Howell, A; Padmanabhan, N; Rubens, RD, 1986) |
| "Treatment with tamoxifen (TM), alone or in combination with cyclophosphamide, methotrexate, and fluorouracil (CMF), was used as an adjuvant to surgery in 433 patients with stage I, II, or III(T3a) breast cancer." | 5.06 | Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. ( Bianco, AR; D'Istria, M; De Placido, S; Delrio, G; Gallo, C; Marinelli, A; Pagliarulo, C; Petrella, G, 1988) |
| "The present paper concerns two multicenter studies on adjuvant therapy with medroxyprogesterone acetate (MAP) for operable N+ breast cancer." | 5.06 | Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. ( Camaggi, CM; Cilenti, G; Fruet, F; Martoni, A; Pannuti, F, 1988) |
| "Following mastectomy for node-positive breast cancer, 261 postmenopausal women were randomized to observation or adjuvant treatment with cyclophosphamide, fluorouracil, prednisone (CFP) alone or combined with tamoxifen (T)." | 5.06 | Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. ( Cullinan, SA; Everson, LK; Ingle, JN; Krook, JE; Martin, JK; Paulsen, JK; Twito, DI; Votava, HJ; Wieand, HS; Wold, LE, 1988) |
| "Three hundred ten patients with Stage II or Stage III breast cancer were entered on an adjuvant protocol consisting of a combination of 5-fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone (FACVP)." | 5.06 | Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. ( Ames, FC; Buzdar, AU; Fraschini, G; Holmes, FA; Hortobagyi, GN; Hug, V; Kau, S; Marcus, C; Martin, RG; Smith, TL, 1988) |
| "Eight hundred eighteen premenopausal or perimenopausal breast cancer patients with axillary node metastases were treated with adjuvant chemotherapy (CMF) with or without endocrine treatment (prednisone, oophorectomy) in two concurrent prospective trials." | 5.06 | Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. ( Castiglione, M; Gelber, RD; Goldhirsch, A, 1988) |
| "We have analyzed the relationship between dose intensity of cyclophosphamide, methotrexate, and fluorouracil (CMF)-containing adjuvant chemotherapy of stage II breast cancer and 3-year relapse-free survival." | 5.06 | Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. ( Hryniuk, W; Levine, MN, 1986) |
| "In a prospective, randomized trial Cancer and Leukemia Group B (CALGB) evaluated CAF chemotherapy (cyclophosphamide + doxorubicin + 5-fluorouracil [5-FU]) v CAF plus tamoxifen (TCAF) in advanced breast cancer." | 5.06 | Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081. ( Aisner, J; Ellison, RR; Ginsberg, SJ; Holland, JF; Kardinal, CG; Kopel, S; Korzun, AH; Perry, MC; Raich, PC; Schilling, A, 1987) |
| "Between 1978 and 1981, 463 evaluable postmenopausal patients 65 years of age or younger with operable breast cancer and metastases in axillary lymph nodes were entered in Ludwig Breast Cancer Study III (Ludwig III) and randomly allocated to receive chemoendocrine therapy with cyclophosphamide, methotrexate, 5-fluorouracil, low-dose continuous prednisone, and tamoxifen (CMFp + T) for 12 monthly cycles, or endocrine therapy alone with prednisone and tamoxifen (p + T) for 1 year, or no adjuvant treatment after mastectomy (observation)." | 5.06 | A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. ( Gelber, RD; Goldhirsch, A, 1986) |
| "Adjuvant therapy after total mastectomy and axillary clearance in postmenopausal women with breast cancer and axillary node metastasis was assessed; chemo-endocrine therapy (cyclophosphamide, methotrexate, fluorouracil, prednisone, and tamoxifen; CMFp + T) was compared with endocrine therapy (prednisone and tamoxifen; p + T), and with no adjuvant treatment in 463 patients aged less than or equal to 65 years." | 5.05 | Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. ( , 1984) |
| "After total mastectomy and partial axillary dissection, 805 premenopausal women with stage II breast cancer were randomized to receive postoperative radiotherapy (RT) alone, RT + cyclophosphamide (C) for 12 monthly cycles, or RT + cyclophosphamide/methotrexate/5-fluorouracil (CMF) for 12 monthly cycles." | 5.05 | Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. ( Andersen, KW; Brincker, H; Mouridsen, HT, 1983) |
| "From January 1980 to August 1982 the Cancer and Leukemia Group B conducted a prospective randomized trial comparing chemoendocrine therapy with T-CAF (cyclophosphamide, adriamycin, and 5-fluorouracil plus tamoxifen) to CAF alone in postmenopausal women with advanced breast cancer." | 5.05 | Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study. ( Ginsberg, S; Kardinal, CG; Perry, MC; Raju, RN; Weinberg, V; Wood, W, 1983) |
| "The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) to two years of intermittent L-phenylalanine mustard (L-PAM) in women with operable breast cancer with histologically positive axillary lymph nodes." | 5.05 | Adjuvant therapy of breast cancer: the Southwest Oncology Group experience. ( Athens, JW; Costanzi, JJ; Foulkes, MA; Glucksberg, H; Knight, WA; O'Bryan, RM; Rivkin, SE; Stephens, RL, 1983) |
| "Between September 1976 and June 1982, 308 patients with operable breast cancer with 1-3 involved axillary nodes were stratified according to institution, type of mastectomy, and time from surgery to protocol entry, and then randomized to receive either six or 12 months of adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)." | 5.05 | Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience. ( Bartolucci, A; Ketcham, A; Liu, C; Marcial, V; Moore, M; Smalley, R; Velez-Garcia, E; Vogel, CL, 1983) |
| "Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval." | 5.05 | Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984) |
| "We report the results of a randomized trial carried out by the Swiss Group for Clinical Cancer Research (SAKK) and in which 230 patients with advanced breast cancer receiving concurrently a hormonal treatment (oophorectomy for pre- and tamoxifen for postmenopausal women) were randomly allocated to three different regimens of combination chemotherapy." | 5.05 | Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer. ( Alberto, P; Brunner, KW; Cavalli, F; Goldhirsch, A; Jungi, WF; Martz, G; Mermillod, B; Pedrazzini, A, 1983) |
| "Eighty-eight postmenopausal women with metastatic breast cancer, in whom estrogen receptors (ER) were positive or unknown, were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders." | 5.05 | Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer. ( Brodovsky, H; Catalano, RB; Creech, RH; Glick, JH; Holroyde, C; Torri, S; Varano, M, 1981) |
| "During the past 4 years, a sequential study was conducted to compare the effect of tamoxifen (TAM) alone and TAM plus 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) in the treatment of advanced breast cancer." | 5.05 | Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial. ( Koyama, H; Terasawa, T; Wada, T, 1981) |
| "Eighty-nine postmenopausal women with metastatic breast cancer, in whom estrogen receptors (ER) were positive or unknown, were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders." | 5.05 | Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial. ( Brodovsky, H; Catalano, RB; Creech, RH; Glick, JH; Holroyde, C; Torri, S; Varano, M, 1980) |
| "Cloned cell lines of human breast cancer can be growth inhibited by tamoxifen and this inhibition can be reversed by estrogen." | 5.05 | Increasing the response rate to cytotoxic chemotherapy by endocrine means. ( Cassidy, J; Lippman, ME; Wesley, M; Young, RC, 1985) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 5.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "Between 1977 and 1980, 118 breast cancer patients with locally advanced disease, T3B-4, any N, M0 or T1-3, tumor positive axillary apex biopsy, were randomized to one of three arms: I: radiotherapy (RT) to the breast and adjacent lymph node areas; II: RT followed by 12 cycles of cyclophosphamide, methotrexate, 5 fluorouracil (CMF) and tamoxifen during the chemotherapy period; III: 2 cycles of adriamycin and vincristine (AV), alternated with 2 cycles of CMF, then RT, followed by another 4 cycles of AV, alternated with 4 CMF; tamoxifen during the entire treatment period." | 5.05 | Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. ( Engelsman, E; Hart, G; Schaake-Koning, C; van der Linden, EH, 1985) |
| "After mastectomy, 265 postmenopausal patients with node-positive breast cancer were stratified according to pathologic nodal status and estrogen-receptor (ER) status and randomized to receive either 12 cycles of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), or CMFP plus tamoxifen (CMFPT), or observation alone." | 5.05 | Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study. ( Bennett, JM; Carbone, PP; Cummings, F; Falkson, G; Kalish, LA; Olson, JE; Taylor, SG; Tormey, DC, 1985) |
| "In this study 263 patients with advanced measurable breast cancer were randomized to receive cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or CMF + tamoxifen (T)." | 5.05 | Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. ( Engelsman, E; Mouridsen, HT; Rose, C; Rotmensz, N; Sylvester, R, 1985) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 5.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "One hundred seventeen postmenopausal advanced breast cancer patients previously untreated with chemotherapy were randomized to receive: cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), CMF and tamoxifen (TMX), and CMF and medroxyprogesterone (MAP)." | 5.05 | Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial. ( Alonso, MC; Avella, A; Beltrán, M; Borrás, J; Bosch, FX; Ojeda, B; Viladiu, P, 1985) |
| "Eighty-one patients with advanced measurable breast cancer were randomized to receive only chemotherapy (Group C) or the same chemotherapy + tamoxifen (Group CH)." | 5.05 | Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study. ( Boccardo, F; Rosso, R; Rubagotti, A; Santi, L, 1985) |
| "Two hundred and sixty-three patients with advanced measurable breast cancer were randomized to receive cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or CMF + tamoxifen (T)." | 5.05 | Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen. ( Engelsmann, E; Mouridsen, HT; Rose, C; Rotmensz, N; Sylvester, R, 1985) |
| "Six-year results of a prospective, randomized clinical trial of three treatment regimens [(1) cytoxan, methotrexate and 5-fluorouracil (CMF); (2) CMF plus the antiestrogen drug, tamoxifen (CMFT); (3) CMFT plus Bacillus Calmette-Guerin (BCG) vaccinations] in 312 women with stage II breast cancer are reported." | 5.05 | Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result. ( Gordon, NH; Hubay, CA; Manni, A; McGuire, WL; Pearson, OH, 1985) |
| "Between November 1, 1976 and December 31, 1981, 826 post-menopausal females with operable breast cancer were included into a trial comparing tamoxifen 40 mg daily for 2 years with no endocrine treatment." | 5.05 | Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer. ( Baral, E; Glas, U; Karnström, L; Nordenskiöld, B; Silfverswärd, C; Theve, NO; Wallgren, A, 1985) |
| "The addition of levamisole, administered in adjunctive manner between the cycles of conventional high dose chemotherapy in patients with hormone resistant end state breast cancer substantially improved the survival of treated patients." | 5.04 | Levamisole: as adjuvant to cyclic chemotherapy in breast cancer. ( Mason, B; Stephens, EJ; Wood, HF, 1978) |
| "Results from randomized trials indicate that treatment with tamoxifen or chemotherapy for primary breast cancer reduces the risk for contralateral breast cancer." | 3.74 | Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. ( Anton-Culver, H; Begg, CB; Bernstein, JL; Bernstein, L; Bertelsen, L; Boice, JD; Capanu, M; Christensen, J; Ejlertsen, B; Haile, RW; Langholz, B; Lynch, CF; Malone, KE; Mellemkjaer, L; Olsen, JH; Shore, RE; Stovall, M; Thomas, DC, 2008) |
| "Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day) + tamoxifen (20 mg/body/day) for 2 years." | 3.70 | Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer. ( Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M, 2000) |
| "Between 1975 and 1986, 326 patients with stage II breast cancer were treated with an adjuvant combination of doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF) following regional therapy (232 modified radical mastectomy, 94 lumpectomies, 304 irradiations)." | 3.69 | Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results. ( Achard, JL; Bélembaogo, E; Charrier, S; Chollet, P; Courtadon, M; Curé, H; Dauplat, J; de Latour, M; Ferrière, JP; Kwiatkowski, F, 1997) |
| "147 stage II pre- and perimenopausal breast cancer patients were treated with cyclophosphamide-methotrexate-5-fluorouracil (CMF)- based adjuvant regimens." | 3.68 | Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients. ( Addamo, GF; Coialbu, T; Costantini, M; Giacchero, A; Guido, T; Repetto, L; Rosso, R; Toma, S, 1992) |
| "The effect of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or tamoxifen treatment on endocrine function was investigated in premenopausal and postmenopausal breast cancer patients." | 3.68 | Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen. ( Balar, DB; Bhatavdekar, JM; Ghosh, N; Giri, DD; Karelia, NH; Patel, DD; Shah, NG; Trivedi, SN; Vora, HH, 1992) |
| "In a comparative study on the effect of CMF (Combination of Cyclophosphamid, Methotroxate and 5-Fluorouracil) on the pre and postmenopausal women with breast cancer, a number of differences were observed in circulating plasma lipid concentration." | 3.68 | Studies on the changes in plasma lipids and lipoproteins in CMF treated breast cancer patients. ( Devi, CS; Marar, T; Subramaniam, S, 1991) |
| "Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement." | 3.67 | Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment. ( Bezwoda, WR; Browde, S; Derman, DP; Goss, G; Lange, M, 1984) |
| "Adjuvant chemotherapy with cyclophosphamide, 5-fluorouracil and methotrexate (CMF)-induced permanent ovarian suppression in 47 of 77 (61%) premenopausal patients with axillary node positive breast cancer." | 3.67 | Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour. ( Beex, LV; Benraad, TJ; Kloppenborg, PW; Mackenzie, MA; Raemaekers, JM; Smals, AG, 1988) |
| "A phase II trial in postmenopausal women with advanced breast cancer naive to cytotoxic treatment for recurrent disease was performed with a combinated chemo-endocrine regimen of prednimustine, methotrexate, mitoxantrone, 5-fluorouracil, and tamoxifen." | 3.67 | Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial. ( Andersson, M; Mouridsen, HT, 1988) |
| "The effect of cyclophosphamide, methotrexate and fluorouracil (CMF) on ovarian function has been studied in 74 pre-menopausal patients with operable breast cancer." | 3.67 | Ovarian function and adjuvant chemotherapy for early breast cancer. ( Moore, JW; Padmanabhan, N; Rubens, RD; Wang, DY, 1987) |
| "The effect of adjuvant CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) and tamoxifen (TM) on hypothalamic-pituitary-ovarian function was studied in 120 women with stage I-II operable breast cancer." | 3.67 | Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. ( Citarella, F; Contegiacomo, A; d'Istria, M; De Placido, S; De Sio, L; Delrio, G; Fasano, S; Iaffaioli, RV; Marinelli, A; Pagliarulo, C, 1986) |
| "One hundred twenty-four patients with metastatic breast cancer were treated with 40 mg of megestrol acetate four times daily." | 3.67 | Megestrol acetate therapy for advanced breast cancer. ( Cohen, SC; Gregory, EJ; Mims, CH; Oines, DW, 1985) |
| "The effect of adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and tamoxifen (TM) on endocrine function was studied in 120 women with stage I-II operable breast cancer." | 3.67 | Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer. ( Bianco, AR; D'Istria, M; De Placido, S; De Sio, L; Delrio, G; Fasano, S; Pagliarulo, C; Ricciardi, I, 1985) |
| "Risk factors for local-regional recurrence of breast cancer were analyzed in a retrospective review of 117 patients treated with adjuvant CMF (Cytoxan [Mead Johnson & Co, Evansville, Ind], methotrexate, 5-fluorouracil) after radical or modified radical mastectomy at the Vincent T." | 3.67 | Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. ( Bachenheimer, L; Beiser, C; Byrne, P; Dritschilo, A; Goldberg, R; Smith, F; Smith, L; Stefanik, D; Ueno, W, 1985) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "The effect of CMF adjuvant therapy (cyclophosphamide, methotrexate, and 5-fluorouracil) on endocrine function was investigated in breast cancer patients." | 3.66 | Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. ( Currie, VE; Dnistrian, AM; Fracchia, AA; Hakes, TB; Kaufman, RJ; Schwartz, MK, 1983) |
| "Forty-seven patients with advanced breast cancer were treated with a combination of prednimustine (P), methotrexate (M), 5-fluorouracil (F), and tamoxifen (TAM)." | 3.66 | Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study. ( Boesen, E; Mouridsen, HT, 1983) |
| "We retrospectively analyzed the role of the dose level of CMF (cyclophosphamide, methotrexate, and fluorouracil) in postoperative adjuvant chemotherapy for breast cancer and in chemotherapy for metastatic breast cancer." | 3.66 | Dose-response effect of adjuvant chemotherapy in breast cancer. ( Bonadonna, G; Valagussa, P, 1981) |
| "One hundred and five patients with metastatic breast cancer were treated with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG (FAC-BCG)." | 3.66 | Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Einhorn, L; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Richman, SP; Tashima, CK, 1979) |
| "A series of 41 patients at the MGH who received 5-drug chemotherapy, cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone, (CMF VP) as adjuvant to surgical treatment of operable breast cancer with 4 or more positive axillary nodes is compared to an analogous group of patients treated with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) reported by Bonadonna et al." | 3.66 | 5-drug adjuvant chemotherapy for breast cancer. ( Carey, RW; Halpern, E; Kaufman, S; Kelley, RM; Lew, RA; Sohier, WD; Weitzman, SA, 1979) |
| "Based upon concepts derived from estrogen receptor studies, a phase II exploratory trial was conducted where tamoxifen (NSC-180973) was administered concomitantly with cytotoxic chemotherapy in postmenopausal patients with advanced breast cancer." | 3.65 | Current overview of EORTC clinical trials with tamoxifen. ( Heuson, JC, 1976) |
| "Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle." | 3.65 | Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974) |
| "Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available." | 2.76 | Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. ( Bighin, C; Boni, L; Cresti, N; Del Mastro, L; Gamucci, T; Garrone, O; Giordano, M; Giraudi, S; Gori, S; Levaggi, A; Magnolfi, E; Michelotti, A; Olmeo, N; Pronzato, P; Scotto, T; Vecchio, C; Venturini, M, 2011) |
| "We used data from the International Breast Cancer Study Group (IBCSG) Trials V and VI." | 2.73 | Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. ( Castiglione-Gertsch, M; Gelber, RD; Gelber, S; Goldhirsch, A; Partridge, A; Winer, E, 2007) |
| "Weight gain is a common side effect observed in women undergoing adjuvant chemotherapy for breast cancer." | 2.70 | Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition. ( Banzi, MC; Bertolini, M; Bondi, M; Del Rio, G; Federico, M; Menozzi, R; Piccinini, L; Valeriani, L; Zironi, S, 2002) |
| "Most patients with lymph node-negative breast cancer are cured by locoregional treatment; however, about 30% relapse." | 2.70 | Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. ( Graeff, H; Harbeck, N; Jänicke, F; Meisner, C; Prechtl, A; Schmitt, M; Selbmann, HK; Sweep, CG; Thomssen, C; Untch, M, 2001) |
| "Amonafide is a new imide derivative of naphthalic acid." | 2.68 | Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). ( Berkowitz, I; Berry, D; Costanza, ME; Duggan, D; Henderson, IC; Kalra, J; Lyss, AP; Ratain, MJ; Shapiro, C; Wu, K, 1995) |
| "Postoperative women with breast cancer but without histopathological evidence of metastases to the axillary lymph nodes or clinical evidence of metastases were studied." | 2.67 | Chemotherapy versus observation in high-risk node-negative breast cancer patients. ( Cooper, MR; Eudey, L; Falkson, G; Gilchrist, KW; Mansour, EG; Osborne, CK; Shatila, AH; Tormey, DC, 1992) |
| "In this study, patients with operable breast cancer T2 or T3, treated by mastectomy + axillary dissection and with invaded axillary nodes (N+), were randomized to receive either: 1) postoperative locoregional and pelvic radiotherapy (RX) and Poly(A)." | 2.67 | Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.). ( Berlie, J; De Gislain, C; Delozier, T; Denis, V; Julien, JP; Lacour, J; Laplanche, A; Mourali, N; Namer, M; Petit, JC, 1991) |
| " When analyzed analogously to previous work, the results confirmed a dose-response relationship: that is, there appeared to be an improved disease-free survival for patients receiving higher doses of adjuvant chemotherapy." | 2.67 | Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. ( Currie, V; Geller, NL; Hakes, TB; Kaufman, R; Petroni, GR, 1990) |
| "Tamoxifen was added to the conventionally timed regimen in postmenopausal women." | 2.66 | Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. ( , 1988) |
| " Addition of chemotherapy with doxorubicin and cyclophosphamide significantly increased the proportion of patients with pulmonary fibrosis compared with patients treated with radiotherapy only or radiotherapy combined with cyclophosphamide, methotrexate and 5-fluorouracil." | 2.66 | Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer. ( Hrafnkelsson, J; Nilsson, K; Söderberg, M, 1987) |
| "Adjuvant treatment of breast cancer with AVCF gave significantly longer disease-free survival than CMF in the group of patients taken as a whole, in the subgroup with lymph node involvement and in the premenopausal subgroup." | 2.66 | Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results. ( Belpomme, D; Delgado, M; Fumoleau, P; Guerrin, J; Le Mevel, B; Mathé, G; Metz, R; Misset, JL; Plagne, R; Reizenstein, P, 1986) |
| "Treatment results are available (Ludwig Breast Cancer Study Group, Lancet i (1984) 1256-1260)." | 2.66 | Adjuvant treatment in operable breast cancer. ( Goldhirsch, A, 1985) |
| "Adjuvant therapy trials in breast cancer have grown steadily more complex since 1971, when the first long-term adjuvant trial in the United States was initiated." | 2.65 | Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience. ( Carbone, PP, 1983) |
| " Both the delay in starting chemotherapy and the significant decrease in percent optimal drug dosage during the first six cycles of therapy are factors that may influence the high frequency of relapse observed in the R." | 2.65 | A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. ( Cooper, MR; Ferree, C; Howard, V; Jackson, DV; Muss, HB; Rhyne, AL; Richards, F; Shore, A; Spurr, CL; Stuart, JJ; White, DR, 1981) |
| "Since in the treatment of advanced breast cancer chemotherapy and the various hormonal manipulations seem recently to have reached a plateau of effectiveness when used alone, it is widely assumed that the combination of both treatment modalities could improve therapeutic results." | 2.65 | [Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer]. ( Alberto, P; Beer, M; Brunner, KW; Cavalli, F; Jungi, WF; Martz, G; Mermillod, B; Obrecht, JP, 1982) |
| "Seventy patients with breast cancer (stage IIIb--IV) were randomized by an "envelope" method into 2 groups, each including 35 persons." | 2.64 | [Combined drug treatment of far-advanced forms of breast cancer]. ( Borisov, AI, 1978) |
| "At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy." | 2.45 | International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. ( Albain, KS; Bedard, PL; Cardoso, F; Costa, A; Cufer, T; Fallowfield, LJ; Kyriakides, S; Pagani, O; Senkus-Konefka, E; Winer, EP, 2009) |
| "Selected patients with inflammatory breast cancer have the potential for long-term survival." | 2.42 | Ten-year outcome after combined modality therapy for inflammatory breast cancer. ( Bertsch, H; Fox, K; Glick, J; Harris, EE; Schultz, D; Solin, LJ, 2003) |
| "Nurses can inform women with breast cancer about the expected changes in body weight after chemotherapy to reduce their uncertainty." | 1.40 | Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens. ( Chen, ML; Jeng, C; Lin, YC; Liu, LN; Miaskowski, C; Wang, JS; Wen, FH, 2014) |
| "Endometrial carcinoma is the commonest female genital tract malignancy in the south of Israel." | 1.30 | Endometrial carcinoma in the south of Israel: study of 231 cases. ( Bar-Dayan, A; Cohen, Y; Glezerman, M; Piura, B; Yanai-Inbar, I, 1997) |
| "All specimens showed residual tumour in the mastectomy specimen or the regional lymph nodes." | 1.29 | Locally advanced breast cancer: is surgery warranted following chemotherapy? ( Eaton, M; Humeniuk, V; Kent, AL; Marshall, N, 1995) |
| "In 165 women with breast cancer who were candidates for mastectomy because the largest diameter of the tumor was 3 cm or more, we administered primary chemotherapy in the attempt to substitute conservative for mutilating surgery." | 1.28 | Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. ( Bartoli, C; Bonadonna, G; Brambilla, C; Coopmans de Yoldi, G; Ferrari, L; Greco, M; Luini, A; Rilke, F; Veronesi, U; Zucali, R, 1990) |
| " Chronic administration of this compound is associated with the development of dose-dependent cardiotoxicity." | 1.27 | [Cytostatic therapy in metastatic breast cancer]. ( Lenzhofer, R; Rainer, H, 1984) |
| "However, comparing 9 breast cancer patients, when having had both short-term and non-short-term CMF treatment, the effects on steroid excretion patterns appear to arise at an early stage." | 1.27 | Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre- and postmenopausal breast cancer. ( Carruba, G; Castagnetta, L; Ciaccio, M; Di Carlo, A; Polito, L; Traina, A, 1985) |
| " While earlier results suggested that adjuvant chemotherapy is especially effective in premenopausal women, newer studies and analyses indicate that appropriate dosage and consistent administration of chemotherapy are of decisive importance." | 1.26 | [Results of, and indications for adjuvant chemotherapy in breast cancer]. ( Brunner, KW; Goldhirsch, A; Joss, R; Sonntag, RW; Tschopp, L, 1981) |
| "Treatment of breast cancer by combination therapy induced luteal insufficiency, anovulatory cycles and sometimes hypergonadotropic amenorrhea in premenopausal women with previously normal mentrual cycles and ovarian function." | 1.26 | The effect of combination chemotherapy on ovarian, hypothalamic and pituitary function in patients with breast cancer. ( Geiger, W; Künzig, HJ; Schmidt-Rhode, P; Schulz, KD; Weymar, P, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 164 (70.09) | 18.7374 |
| 1990's | 48 (20.51) | 18.2507 |
| 2000's | 16 (6.84) | 29.6817 |
| 2010's | 6 (2.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, LN | 1 |
| Wen, FH | 1 |
| Miaskowski, C | 2 |
| Lin, YC | 1 |
| Wang, JS | 1 |
| Jeng, C | 1 |
| Chen, ML | 1 |
| Abdel-Fatah, TM | 1 |
| McArdle, SE | 1 |
| Johnson, C | 1 |
| Moseley, PM | 1 |
| Ball, GR | 1 |
| Pockley, AG | 1 |
| Ellis, IO | 1 |
| Rees, RC | 1 |
| Chan, SY | 1 |
| Viale, G | 2 |
| Giobbie-Hurder, A | 1 |
| Gusterson, BA | 2 |
| Maiorano, E | 2 |
| Mastropasqua, MG | 2 |
| Sonzogni, A | 1 |
| Mallon, E | 1 |
| Colleoni, M | 3 |
| Castiglione-Gertsch, M | 5 |
| Regan, MM | 2 |
| Price, KN | 3 |
| Brown, RW | 2 |
| Golouh, R | 2 |
| Crivellari, D | 2 |
| Karlsson, P | 2 |
| Öhlschlegel, C | 2 |
| Gelber, RD | 9 |
| Goldhirsch, A | 14 |
| Coates, AS | 3 |
| Cardoso, F | 1 |
| Bedard, PL | 1 |
| Winer, EP | 1 |
| Pagani, O | 1 |
| Senkus-Konefka, E | 1 |
| Fallowfield, LJ | 1 |
| Kyriakides, S | 1 |
| Costa, A | 1 |
| Cufer, T | 1 |
| Albain, KS | 1 |
| Kumar, K | 1 |
| Vamsy, M | 1 |
| Jamil, K | 1 |
| Cole, BF | 1 |
| Roncadin, M | 1 |
| Chua, BH | 1 |
| Murray, E | 1 |
| Gruber, G | 1 |
| Del Mastro, L | 3 |
| Boni, L | 1 |
| Michelotti, A | 1 |
| Gamucci, T | 1 |
| Olmeo, N | 1 |
| Gori, S | 1 |
| Giordano, M | 1 |
| Garrone, O | 2 |
| Pronzato, P | 1 |
| Bighin, C | 1 |
| Levaggi, A | 1 |
| Giraudi, S | 1 |
| Cresti, N | 1 |
| Magnolfi, E | 1 |
| Scotto, T | 1 |
| Vecchio, C | 1 |
| Venturini, M | 2 |
| Cocconi, G | 1 |
| Di Blasio, B | 1 |
| Boni, C | 1 |
| Bisagni, G | 1 |
| Ceci, G | 1 |
| Rondini, E | 1 |
| Bella, M | 1 |
| Leonardi, F | 1 |
| Savoldi, L | 1 |
| Camisa, R | 1 |
| Bruzzi, P | 3 |
| Del Rio, G | 1 |
| Zironi, S | 1 |
| Valeriani, L | 1 |
| Menozzi, R | 1 |
| Bondi, M | 1 |
| Bertolini, M | 1 |
| Piccinini, L | 1 |
| Banzi, MC | 1 |
| Federico, M | 1 |
| Rivkin, SE | 4 |
| Green, SJ | 2 |
| Lew, D | 1 |
| Costanzi, JJ | 2 |
| Athens, JW | 2 |
| Osborne, CK | 3 |
| Vaughn, CB | 1 |
| Martino, S | 1 |
| Harris, EE | 1 |
| Schultz, D | 1 |
| Bertsch, H | 1 |
| Fox, K | 1 |
| Glick, J | 1 |
| Solin, LJ | 1 |
| Fisher, B | 4 |
| Jeong, JH | 1 |
| Anderson, S | 1 |
| Wolmark, N | 1 |
| Jansen, C | 1 |
| Dodd, M | 1 |
| Dowling, G | 1 |
| Kramer, J | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengeçti, S | 1 |
| Berkarda, B | 1 |
| Beresford, MJ | 1 |
| Burcombe, R | 1 |
| Ah-See, ML | 1 |
| Stott, D | 1 |
| Makris, A | 1 |
| Partridge, A | 1 |
| Gelber, S | 1 |
| Winer, E | 1 |
| Genet, D | 1 |
| Lejeune, C | 1 |
| Bonnier, P | 1 |
| Aubard, Y | 1 |
| Venat-Bouvet, L | 1 |
| Adjadj, DJ | 1 |
| Martin, J | 1 |
| Labourey, JL | 1 |
| Benyoub, A | 1 |
| Clavère, P | 1 |
| Lebrun-Ly, V | 1 |
| Juin, P | 1 |
| Piana, L | 1 |
| Tubiana-Mathieu, N | 1 |
| Buijs, C | 1 |
| Rodenhuis, S | 1 |
| Seynaeve, CM | 1 |
| van Hoesel, QG | 1 |
| van der Wall, E | 1 |
| Smit, WJ | 1 |
| Nooij, MA | 1 |
| Voest, E | 1 |
| Hupperets, P | 1 |
| TenVergert, EM | 1 |
| van Tinteren, H | 1 |
| Willemse, PH | 1 |
| Mourits, MJ | 1 |
| Aaronson, NK | 1 |
| Post, WJ | 1 |
| de Vries, EG | 1 |
| Bertelsen, L | 1 |
| Bernstein, L | 1 |
| Olsen, JH | 1 |
| Mellemkjaer, L | 1 |
| Haile, RW | 1 |
| Lynch, CF | 1 |
| Malone, KE | 1 |
| Anton-Culver, H | 1 |
| Christensen, J | 1 |
| Langholz, B | 1 |
| Thomas, DC | 1 |
| Begg, CB | 1 |
| Capanu, M | 1 |
| Ejlertsen, B | 1 |
| Stovall, M | 1 |
| Boice, JD | 1 |
| Shore, RE | 1 |
| Bernstein, JL | 1 |
| Perin, T | 1 |
| Kovács, A | 1 |
| Pillay, K | 1 |
| Braye, S | 1 |
| Grigolato, P | 1 |
| Rusca, T | 1 |
| Bonadonna, G | 15 |
| Rossi, A | 8 |
| Tancini, G | 5 |
| Valagussa, P | 14 |
| Clavel, B | 1 |
| Cappelaere, JP | 1 |
| Guerin, J | 1 |
| Klein, T | 1 |
| Pommatau, E | 1 |
| Berlie, J | 2 |
| Brincker, H | 3 |
| Mouridsen, HT | 12 |
| Andersen, KW | 3 |
| Kardinal, CG | 3 |
| Perry, MC | 3 |
| Weinberg, V | 1 |
| Wood, W | 1 |
| Ginsberg, S | 2 |
| Raju, RN | 1 |
| Carbone, PP | 5 |
| Wood, WC | 2 |
| Knight, WA | 1 |
| Glucksberg, H | 3 |
| Foulkes, MA | 1 |
| Stephens, RL | 1 |
| O'Bryan, RM | 1 |
| Velez-Garcia, E | 2 |
| Moore, M | 1 |
| Vogel, CL | 2 |
| Marcial, V | 1 |
| Ketcham, A | 1 |
| Bartolucci, A | 1 |
| Liu, C | 1 |
| Smalley, R | 1 |
| Jungi, WF | 6 |
| Holmes, FA | 3 |
| Yap, HY | 3 |
| Esparza, L | 1 |
| Buzdar, AU | 5 |
| Hortobagyi, GN | 7 |
| Blumenschein, GR | 4 |
| Hubay, CA | 3 |
| Arafah, B | 1 |
| Gordon, NH | 3 |
| Guyton, SP | 1 |
| Crowe, JP | 2 |
| Palshof, T | 2 |
| Tormey, C | 1 |
| Foulkes, M | 1 |
| Brambilla, C | 7 |
| Wallgren, A | 2 |
| Baral, E | 2 |
| Beling, U | 1 |
| Carstensen, J | 1 |
| Friberg, S | 1 |
| Glas, U | 2 |
| Kaigas, M | 1 |
| Skoog, L | 1 |
| Bezwoda, WR | 2 |
| Derman, DP | 2 |
| Browde, S | 2 |
| Goss, G | 1 |
| Lange, M | 2 |
| Di Fronzo, G | 1 |
| Marchini, S | 2 |
| Rainer, H | 2 |
| Lenzhofer, R | 1 |
| Veronesi, U | 6 |
| Leone, BA | 1 |
| Rabinovich, MG | 1 |
| Strauss, E | 1 |
| Arévalo, E | 1 |
| Larrad Jiménez, A | 1 |
| Ruiz-Tartas, A | 1 |
| Zapatero Gaviria, J | 1 |
| López Lazareno, N | 1 |
| Cavalli, F | 4 |
| Pedrazzini, A | 1 |
| Martz, G | 3 |
| Brunner, KW | 5 |
| Mermillod, B | 2 |
| Alberto, P | 3 |
| Dnistrian, AM | 2 |
| Schwartz, MK | 2 |
| Fracchia, AA | 2 |
| Kaufman, RJ | 1 |
| Hakes, TB | 3 |
| Currie, VE | 1 |
| Lee, YT | 1 |
| Hirshaut, Y | 1 |
| Kesselheim, H | 1 |
| Sulkes, A | 1 |
| Brufman, G | 1 |
| Rizel, S | 1 |
| Weshler, Z | 1 |
| Biran, S | 1 |
| Fuks, Z | 1 |
| De Luca, L | 1 |
| Marsilio, P | 1 |
| Bian, AR | 1 |
| Geatti, O | 1 |
| Englaro, E | 1 |
| Nadalin, L | 1 |
| Englaro, GC | 1 |
| Glick, JH | 2 |
| Creech, RH | 2 |
| Torri, S | 2 |
| Holroyde, C | 2 |
| Brodovsky, H | 2 |
| Catalano, RB | 2 |
| Varano, M | 2 |
| Senn, HJ | 5 |
| Holland, JF | 4 |
| Wada, T | 1 |
| Koyama, H | 1 |
| Terasawa, T | 1 |
| Kiang, DT | 2 |
| Kennedy, BJ | 2 |
| Boesen, E | 1 |
| Mobbs, BG | 1 |
| Carter, SK | 3 |
| Cooper, MR | 3 |
| Rhyne, AL | 1 |
| Muss, HB | 1 |
| Ferree, C | 1 |
| Richards, F | 1 |
| White, DR | 1 |
| Stuart, JJ | 1 |
| Jackson, DV | 1 |
| Howard, V | 1 |
| Shore, A | 1 |
| Spurr, CL | 1 |
| von Maillot, K | 1 |
| Egger, H | 1 |
| Gunselmann, W | 1 |
| Levitt, SH | 1 |
| Potish, RA | 1 |
| Heuson, JC | 2 |
| Sylvester, R | 4 |
| Engelsman, E | 5 |
| Bajetta, E | 2 |
| Tesoro Tess, JD | 1 |
| Banfi, A | 2 |
| Amgwerd, R | 2 |
| Hochuli, R | 1 |
| Ammann, J | 1 |
| Engelhart, G | 2 |
| Heinz, C | 2 |
| Wick, A | 2 |
| Enderlin, F | 2 |
| Creux, G | 2 |
| Simon, B | 1 |
| Lanz, R | 2 |
| Bigler, R | 2 |
| Seiler, S | 1 |
| Tranum, BL | 1 |
| McDonald, B | 1 |
| Thigpen, T | 1 |
| Vaughn, C | 2 |
| Wilson, H | 1 |
| Maloney, T | 2 |
| Costanzi, J | 2 |
| Bickers, J | 1 |
| el Mawli, NG | 1 |
| Palmer, R | 1 |
| Hoogstraten, B | 2 |
| Heilburn, L | 1 |
| Rasmusen, S | 1 |
| Canellos, GP | 2 |
| Hellman, S | 1 |
| Rasmussen, S | 1 |
| Tranum, B | 1 |
| Gad-el-Mawla, N | 1 |
| Athens, J | 1 |
| McCracken, J | 1 |
| Beer, M | 1 |
| Obrecht, JP | 2 |
| Paterson, AH | 1 |
| Agarwal, M | 1 |
| Lees, A | 1 |
| Hanson, J | 1 |
| Szafran, O | 1 |
| Nemoto, T | 1 |
| Horton, J | 1 |
| Simon, R | 1 |
| Dao, TL | 1 |
| Rosner, D | 1 |
| Cunningham, T | 1 |
| Sponzo, R | 1 |
| Snyderman, M | 1 |
| Kalman, AM | 1 |
| Thompson, T | 1 |
| Joss, R | 2 |
| Sonntag, RW | 2 |
| Tschopp, L | 1 |
| Chlebowski, RT | 1 |
| Weiner, JM | 1 |
| Luce, J | 1 |
| Hestorff, R | 1 |
| Lang, JE | 1 |
| Reynolds, R | 1 |
| Godfrey, T | 1 |
| Ryden, VM | 1 |
| Bateman, JR | 1 |
| Melchert, F | 1 |
| Kreienberg, R | 1 |
| von Nathusius, U | 1 |
| Queisser, W | 1 |
| Bissett, D | 1 |
| Jodrell, D | 1 |
| Harnett, AN | 1 |
| Habeshaw, T | 1 |
| Kaye, SB | 1 |
| Evans, D | 1 |
| Williams, M | 1 |
| Canney, PA | 1 |
| Colucci, G | 1 |
| Romito, S | 1 |
| Gebbia, V | 1 |
| Pacilio, G | 1 |
| Giotta, F | 1 |
| Testa, A | 1 |
| Pezzella, G | 1 |
| Durini, E | 1 |
| Agostara, B | 1 |
| Cariello, S | 1 |
| Kent, AL | 1 |
| Eaton, M | 1 |
| Marshall, N | 1 |
| Humeniuk, V | 1 |
| Wiltschke, C | 1 |
| Krainer, M | 1 |
| Budinsky, AC | 1 |
| Berger, A | 1 |
| Müller, C | 1 |
| Zeillinger, R | 1 |
| Speiser, P | 1 |
| Kubista, E | 2 |
| Eibl, M | 1 |
| Zielinski, CC | 2 |
| Houston, SJ | 1 |
| Richards, MA | 3 |
| Bentley, AE | 1 |
| Smith, P | 2 |
| Rubens, RD | 5 |
| Gion, M | 1 |
| Mione, R | 1 |
| Pappagallo, GL | 1 |
| Gatti, C | 1 |
| Nascimben, O | 1 |
| Bari, M | 1 |
| Leon, AE | 1 |
| Vinante, O | 1 |
| Bruscagnin, G | 1 |
| Bhardwaj, S | 1 |
| Norton, L | 1 |
| Zilembo, N | 1 |
| Buzzoni, R | 2 |
| Noberasco, C | 1 |
| Celio, L | 1 |
| Bichisao, E | 1 |
| Smith, IE | 2 |
| Powles, TJ | 1 |
| Bertelli, G | 1 |
| Guelfi, M | 1 |
| Pastorino, S | 1 |
| Rosso, R | 4 |
| Sertoli, MR | 2 |
| De Candis, D | 1 |
| Antonelli, G | 1 |
| Willers, H | 1 |
| Würschmidt, F | 1 |
| Janik, I | 1 |
| Bünemann, H | 1 |
| Heilmann, HP | 1 |
| Ferrière, JP | 1 |
| Charrier, S | 1 |
| Curé, H | 1 |
| Kwiatkowski, F | 1 |
| Courtadon, M | 1 |
| Bélembaogo, E | 1 |
| de Latour, M | 1 |
| Achard, JL | 1 |
| Dauplat, J | 1 |
| Chollet, P | 1 |
| Maibach, R | 1 |
| Castiglione, M | 3 |
| Leyvraz, S | 1 |
| Schildknecht, O | 1 |
| Siegenthaler, P | 1 |
| Kling, KM | 1 |
| Ostrzega, N | 1 |
| Schmit, P | 1 |
| Piura, B | 1 |
| Bar-Dayan, A | 1 |
| Cohen, Y | 1 |
| Yanai-Inbar, I | 1 |
| Glezerman, M | 1 |
| Gasparini, G | 1 |
| Barbareschi, M | 1 |
| Doglioni, C | 1 |
| Palma, PD | 1 |
| Mauri, FA | 1 |
| Boracchi, P | 1 |
| Bevilacqua, P | 1 |
| Caffo, O | 1 |
| Morelli, L | 1 |
| Verderio, P | 1 |
| Dhingra, K | 1 |
| Frye, D | 1 |
| Newman, RA | 1 |
| Walters, R | 1 |
| Theriault, R | 1 |
| Fraschini, G | 3 |
| Smith, T | 1 |
| Buzdar, A | 1 |
| Costanza, ME | 1 |
| Berry, D | 1 |
| Henderson, IC | 2 |
| Ratain, MJ | 1 |
| Wu, K | 1 |
| Shapiro, C | 1 |
| Duggan, D | 1 |
| Kalra, J | 1 |
| Berkowitz, I | 1 |
| Lyss, AP | 1 |
| Miles, DW | 1 |
| Harris, WH | 1 |
| Gillett, CE | 1 |
| Barnes, DM | 1 |
| Hata, Y | 1 |
| Takahashi, H | 1 |
| Sasaki, F | 1 |
| Ogita, M | 1 |
| Uchino, J | 1 |
| Yoshimoto, M | 1 |
| Akasaka, Y | 1 |
| Nakanishi, Y | 1 |
| Sawada, Y | 1 |
| Jänicke, F | 1 |
| Prechtl, A | 1 |
| Thomssen, C | 1 |
| Harbeck, N | 1 |
| Meisner, C | 1 |
| Untch, M | 1 |
| Sweep, CG | 1 |
| Selbmann, HK | 1 |
| Graeff, H | 1 |
| Schmitt, M | 1 |
| Litman, HJ | 1 |
| Sauerbrei, W | 1 |
| Bonetti, M | 1 |
| Schumacher, M | 1 |
| Bastert, G | 1 |
| Rudenstam, CM | 1 |
| Schmoor, C | 1 |
| Lindtner, J | 1 |
| Collins, J | 1 |
| Thürlimann, B | 1 |
| Holmberg, SB | 1 |
| Beyerle, C | 1 |
| Neumann, RL | 1 |
| Rose, DP | 1 |
| Davis, TE | 1 |
| Yonemoto, RH | 1 |
| Tan, MS | 1 |
| Byron, RL | 1 |
| Riihimaki, DU | 1 |
| Keating, J | 1 |
| Jacobs, W | 1 |
| Obrecht, P | 1 |
| Maurice, P | 1 |
| Sprenger, F | 1 |
| Hochueli, R | 1 |
| Simeon, B | 1 |
| Kaufmann, M | 3 |
| Kubli, F | 1 |
| Drings, P | 1 |
| Lammers, G | 1 |
| Borisov, AI | 1 |
| Schaake, C | 1 |
| Hamersma, E | 1 |
| Buzdar, AV | 1 |
| Gutterman, JU | 3 |
| Tashima, CK | 3 |
| Hersh, EM | 2 |
| Gehan, EA | 1 |
| Stephens, EJ | 1 |
| Wood, HF | 1 |
| Mason, B | 1 |
| Krutchik, AN | 1 |
| Benjamin, RS | 1 |
| Bodey, GP | 1 |
| Burgess, MA | 1 |
| Einhorn, L | 1 |
| Richman, SP | 1 |
| Carey, RW | 1 |
| Sohier, WD | 1 |
| Kaufman, S | 1 |
| Weitzman, SA | 1 |
| Kelley, RM | 1 |
| Lew, RA | 1 |
| Halpern, E | 1 |
| Schulz, KD | 1 |
| Schmidt-Rhode, P | 1 |
| Weymar, P | 1 |
| Künzig, HJ | 1 |
| Geiger, W | 1 |
| Lozada, JA | 1 |
| Grillo-López, A | 1 |
| Otis, PT | 1 |
| Armentrout, SA | 1 |
| Bocklage, T | 1 |
| Lee, KR | 1 |
| Belinson, JL | 1 |
| Toma, S | 1 |
| Repetto, L | 1 |
| Giacchero, A | 1 |
| Coialbu, T | 1 |
| Costantini, M | 1 |
| Addamo, GF | 1 |
| Guido, T | 1 |
| Bhatavdekar, JM | 1 |
| Shah, NG | 1 |
| Patel, DD | 1 |
| Karelia, NH | 1 |
| Trivedi, SN | 1 |
| Vora, HH | 1 |
| Ghosh, N | 1 |
| Giri, DD | 1 |
| Balar, DB | 1 |
| Boccardo, F | 3 |
| Rubagotti, A | 3 |
| Amoroso, D | 1 |
| Sismondi, P | 2 |
| Genta, F | 1 |
| Nenci, I | 2 |
| Piffanelli, A | 2 |
| Farris, A | 1 |
| Castagnetta, L | 2 |
| Traina, A | 2 |
| Mansour, EG | 2 |
| Eudey, L | 1 |
| Tormey, DC | 8 |
| Shatila, AH | 2 |
| Gilchrist, KW | 3 |
| Falkson, G | 7 |
| Sbalzarini, G | 1 |
| Pandolfi, C | 1 |
| Labadini, A | 1 |
| Cascinelli, N | 1 |
| Greco, M | 2 |
| Morabito, A | 1 |
| Bufalino, R | 1 |
| Testori, A | 1 |
| Baldini, MT | 1 |
| Andreola, S | 1 |
| Leo, E | 1 |
| Galluzzo, D | 1 |
| Rilke, F | 2 |
| Mueller, CB | 1 |
| Lesperance, ML | 1 |
| Luboinski, G | 1 |
| Nagadowska, M | 1 |
| Pienkowski, T | 1 |
| Lacour, J | 1 |
| Laplanche, A | 1 |
| Delozier, T | 1 |
| Mourali, N | 1 |
| Julien, JP | 1 |
| De Gislain, C | 1 |
| Namer, M | 1 |
| Petit, JC | 1 |
| Denis, V | 1 |
| Subramaniam, S | 1 |
| Marar, T | 1 |
| Devi, CS | 1 |
| Hartmann, LC | 1 |
| Marschke, RF | 2 |
| Schaid, DJ | 1 |
| Ingle, JN | 4 |
| Bethune, WA | 1 |
| Zambetti, M | 4 |
| Mikl, J | 1 |
| Aiginger, P | 1 |
| Czerwenka, K | 1 |
| Salzer, H | 1 |
| Sevelda, P | 1 |
| Spona, J | 2 |
| Staffen, A | 1 |
| Jodrell, DI | 1 |
| Mansi, JL | 1 |
| Pearson, MC | 1 |
| Walsh, G | 1 |
| Ashley, S | 1 |
| Sinnett, HD | 1 |
| McKinna, JA | 1 |
| Bianco, AR | 3 |
| Gallo, C | 2 |
| Perrone, F | 1 |
| Matano, E | 1 |
| Pagliarulo, C | 4 |
| De Placido, S | 4 |
| Shanta, V | 1 |
| Krishnamurthi, S | 1 |
| O'Reilly, SM | 2 |
| Camplejohn, RS | 1 |
| Millis, RR | 1 |
| Falkson, HC | 2 |
| Gray, R | 3 |
| Wolberg, WH | 1 |
| Gillchrist, KW | 1 |
| Harris, JE | 1 |
| Cappellini, M | 1 |
| Isola, G | 1 |
| Scanni, A | 1 |
| Santi, L | 2 |
| Camoriano, JK | 1 |
| Loprinzi, CL | 1 |
| Therneau, TM | 1 |
| Krook, JE | 3 |
| Veeder, MH | 1 |
| Geller, NL | 1 |
| Petroni, GR | 1 |
| Currie, V | 1 |
| Kaufman, R | 1 |
| Howell, A | 2 |
| George, WD | 1 |
| Fentiman, IS | 1 |
| Chaudary, MA | 1 |
| Crowther, D | 1 |
| Ferrari, L | 1 |
| Luini, A | 1 |
| Bartoli, C | 1 |
| Coopmans de Yoldi, G | 1 |
| Zucali, R | 1 |
| Gilchrist, K | 1 |
| Grage, T | 1 |
| Wolter, J | 1 |
| Woll, JE | 1 |
| Cummings, FJ | 3 |
| Becher, R | 1 |
| Höfeler, H | 1 |
| Kloke, O | 1 |
| Kurschel, E | 1 |
| Schilcher, RB | 1 |
| Weinhardt, O | 1 |
| Wandl, U | 1 |
| Schmidt, CG | 1 |
| Cheson, BD | 1 |
| Taylor, SG | 2 |
| Knuiman, MW | 1 |
| Sleeper, LA | 1 |
| Olson, JE | 2 |
| Rosenthal, SN | 1 |
| Swain, SM | 2 |
| Lippman, ME | 3 |
| Egan, EF | 1 |
| Drake, JC | 1 |
| Steinberg, SM | 1 |
| Allegra, CJ | 1 |
| Kessel, IL | 1 |
| De Moor, NG | 1 |
| Dansey, R | 1 |
| Seymour, L | 1 |
| Stewart, HJ | 1 |
| Jonat, W | 2 |
| Abel, U | 2 |
| Jakesz, R | 1 |
| Reiner, G | 1 |
| Schemper, M | 1 |
| Reiner, A | 1 |
| Blijham, G | 1 |
| Dittrich, D | 1 |
| Schutte, B | 1 |
| Reynders, M | 1 |
| Pearson, OH | 2 |
| Marshall, JS | 1 |
| Arafah, BM | 1 |
| McGuire, W | 1 |
| Padmanabhan, N | 2 |
| Marinelli, A | 2 |
| Petrella, G | 1 |
| D'Istria, M | 3 |
| Delrio, G | 3 |
| Pannuti, F | 1 |
| Martoni, A | 1 |
| Cilenti, G | 1 |
| Camaggi, CM | 1 |
| Fruet, F | 1 |
| Ciaccio, M | 1 |
| Carruba, G | 1 |
| Polito, L | 1 |
| Di Carlo, A | 1 |
| Cassidy, J | 1 |
| Wesley, M | 1 |
| Young, RC | 2 |
| Everson, LK | 2 |
| Wieand, HS | 1 |
| Martin, JK | 1 |
| Votava, HJ | 1 |
| Wold, LE | 1 |
| Cullinan, SA | 2 |
| Paulsen, JK | 1 |
| Twito, DI | 1 |
| Dombernowsky, P | 2 |
| Hansen, M | 1 |
| Overgaard, M | 1 |
| Panduro, J | 2 |
| Rose, C | 4 |
| Axelsson, CK | 1 |
| Andersen, J | 1 |
| Hrafnkelsson, J | 1 |
| Nilsson, K | 1 |
| Söderberg, M | 1 |
| Smith, TL | 1 |
| Kau, S | 1 |
| Marcus, C | 1 |
| Hug, V | 3 |
| Ames, FC | 1 |
| Martin, RG | 1 |
| Theriault, RL | 1 |
| Kau, SW | 1 |
| Jabboury, K | 1 |
| Kallioniemi, OP | 1 |
| Blanco, G | 1 |
| Alavaikko, M | 1 |
| Hietanen, T | 1 |
| Mattila, J | 1 |
| Lauslahti, K | 1 |
| Lehtinen, M | 1 |
| Koivula, T | 1 |
| Rank, F | 1 |
| Jakobsen, A | 1 |
| Korzun, AH | 2 |
| Rice, MA | 1 |
| Ahmann, FR | 1 |
| Jones, SE | 1 |
| Moon, TE | 1 |
| Thames, HD | 1 |
| Polyzos, A | 1 |
| Johnston, D | 1 |
| Beex, LV | 1 |
| Mackenzie, MA | 1 |
| Raemaekers, JM | 1 |
| Smals, AG | 1 |
| Benraad, TJ | 1 |
| Kloppenborg, PW | 1 |
| Andersson, M | 2 |
| Mathé, G | 2 |
| Misset, JL | 2 |
| Plagne, R | 1 |
| Reizenstein, P | 1 |
| Belpomme, D | 1 |
| Le Mevel, B | 1 |
| Guerrin, J | 1 |
| Fumoleau, P | 1 |
| Metz, R | 2 |
| Delgado, M | 2 |
| Hryniuk, W | 1 |
| Levine, MN | 1 |
| Semiglazov, VF | 1 |
| Moiseenko, VM | 1 |
| Ivanova, OA | 1 |
| Wang, DY | 1 |
| Moore, JW | 1 |
| Ginsberg, SJ | 1 |
| Raich, PC | 1 |
| Ellison, RR | 1 |
| Kopel, S | 1 |
| Schilling, A | 1 |
| Aisner, J | 1 |
| Fasano, S | 2 |
| Citarella, F | 1 |
| De Sio, L | 2 |
| Contegiacomo, A | 1 |
| Iaffaioli, RV | 1 |
| Gelman, RS | 2 |
| Pretorius, FJ | 1 |
| Gregory, EJ | 1 |
| Cohen, SC | 1 |
| Oines, DW | 1 |
| Mims, CH | 1 |
| Greenberg, EJ | 1 |
| Dillon, HJ | 1 |
| Ricciardi, I | 1 |
| Schaake-Koning, C | 1 |
| van der Linden, EH | 1 |
| Hart, G | 1 |
| Scarsi, PG | 1 |
| Kalish, LA | 1 |
| Cummings, F | 1 |
| Bennett, JM | 2 |
| Gough, MH | 1 |
| Durrant, KR | 1 |
| Giraud-Saunders, AM | 1 |
| Paine, CH | 1 |
| McPherson, K | 1 |
| Vessey, MP | 1 |
| Bowman, WD | 1 |
| Windschitl, HE | 1 |
| Laurie, JA | 1 |
| Pfeifle, DM | 1 |
| Rotmensz, N | 2 |
| Byrne, P | 2 |
| Desai, A | 1 |
| White, C | 1 |
| DeConti, R | 1 |
| Vogel, C | 1 |
| Krementz, E | 1 |
| Muggia, F | 1 |
| Doroshow, J | 1 |
| Plotkin, D | 1 |
| Viladiu, P | 1 |
| Alonso, MC | 1 |
| Avella, A | 1 |
| Beltrán, M | 1 |
| Borrás, J | 1 |
| Ojeda, B | 1 |
| Bosch, FX | 1 |
| Gay, J | 1 |
| Goldman, A | 1 |
| Engelsmann, E | 1 |
| Manni, A | 1 |
| McGuire, WL | 1 |
| Karnström, L | 1 |
| Nordenskiöld, B | 1 |
| Theve, NO | 1 |
| Silfverswärd, C | 1 |
| Pedersen, L | 1 |
| Stefanik, D | 1 |
| Goldberg, R | 1 |
| Smith, F | 1 |
| Ueno, W | 1 |
| Smith, L | 1 |
| Bachenheimer, L | 1 |
| Beiser, C | 1 |
| Dritschilo, A | 1 |
| Keiling, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Prevot, G | 1 |
| Grimbert, J | 1 |
| Gardner, B | 1 |
| Sokolova, VD | 2 |
| Sharoukhova, KS | 1 |
| Goncharova, MG | 1 |
| Murav'eva, NI | 1 |
| Smirnova, KD | 1 |
| Lee, JM | 1 |
| Abeloff, MD | 1 |
| Lenhard, RE | 1 |
| Baker, RR | 1 |
| Devita, VT | 1 |
| Gold, GL | 1 |
| Chabner, BA | 1 |
| Schein, PS | 1 |
| Ravdin, RG | 1 |
| Ausman, RK | 1 |
| Slack, NH | 2 |
| Moore, GE | 1 |
| Noer, RJ | 1 |
| Blumenson, LE | 1 |
| Bross, ID | 1 |
| Perevodchikova, NI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression With Triptorelin Vs. Control in Young Breast Cancer Patients. A Randomized Phase III Multicenter Study [PROMISE][NCT00311636] | Phase 3 | 280 participants (Anticipated) | Interventional | 2003-09-30 | Completed | ||
| Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk[NCT02862990] | 343 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| A Phase III Randomized Controlled Trial of Prophylactic Cranial Irradiation in Patients With Advanced Triple Negative Breast Cancer Who Had a Response to First Line Chemotherapy[NCT02448576] | 326 participants (Anticipated) | Interventional | 2017-08-31 | Not yet recruiting | |||
| Adjuvant Chemotherapy in Node-negative Breast Cancer: Chemo N0[NCT01317108] | Phase 3 | 689 participants (Actual) | Interventional | 1993-06-30 | Completed | ||
| A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer[NCT00001338] | Phase 3 | 65 participants | Interventional | 1993-06-30 | Completed | ||
| Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer[NCT03210441] | 204 participants (Anticipated) | Observational | 2014-05-06 | Recruiting | |||
| Prospective Clinical Trial to Assess a Mini-invasive Pre-surgical Procedure to Detect Residual Breast or Axillary Disease in Patients With cT1-T2-T3 cN0/N1 Breast Cancer in Complete Clinical/Radiological Remission After Primary Chemotherapy[NCT05951699] | 105 participants (Anticipated) | Observational | 2022-04-28 | Recruiting | |||
| Primary Chemotherapy Combined With Perioperative Chemotherapy In Operable Breast Cancer[NCT00301548] | Phase 2 | 172 participants | Interventional | 2000-02-29 | Completed | ||
| Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study[NCT00888082] | Phase 3 | 102 participants (Anticipated) | Interventional | Withdrawn | |||
| Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890] | 89 participants (Actual) | Observational | 2004-02-29 | Completed | |||
| Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial[NCT00001250] | Phase 2 | 130 participants | Interventional | 1989-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for fluorouracil and Menopause
| Article | Year |
|---|---|
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
Topics: Age Factors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2009 |
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Potential mechanisms for chemotherapy-induced impairments in cognitive function.
Topics: Anemia; Animals; Antineoplastic Agents; Attention; Blood-Brain Barrier; Cognition Disorders; Cycloph | 2005 |
[Adjuvant chemotherapy in breast cancer: status in 1984].
Topics: Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Drug Th | 1984 |
Hormone receptors. An update and application.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Combined Modality The | 1984 |
Adjuvant systemic therapy in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical | 1984 |
The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Topics: Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Dr | 1981 |
Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Topics: Adult; Age Factors; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chem | 1998 |
[Adjuvant (preventive) postoperative chemotherapy in breast carcinoma].
Topics: Breast Neoplasms; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; Humans; Melphalan; Menopause | 1978 |
Adjuvant chemotherapy for node-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Combined Modality Th | 1989 |
Controversies in the treatment of cancer of the breast.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1987 |
Adjuvant systemic therapy for resectable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1985 |
Hormono-chemotherapy in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1985 |
Single and combination nonhormonal chemotherapy in breast cancer.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bre | 1972 |
137 trials available for fluorouracil and Menopause
| Article | Year |
|---|---|
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2010 |
Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.
Topics: Age Factors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2011 |
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy | 2011 |
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2002 |
Weight gain in women with breast cancer treated with adjuvant cyclophosphomide, methotrexate and 5-fluorouracil. Analysis of resting energy expenditure and body composition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Breast Neoplasms; Chemotherapy, Ad | 2002 |
Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Axil | 2003 |
Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2004 |
Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dat | 2006 |
Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Co | 2007 |
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemothe | 2007 |
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2008 |
Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
[Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
Topics: Androstanols; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as T | 1982 |
Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; C | 1983 |
Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1983 |
Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1983 |
Cancer and Leukemia Group B adjuvant chemotherapy trials in postmastectomy breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1983 |
Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1983 |
Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as | 1983 |
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1984 |
Adjuvant systemic therapy in primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Clinical | 1984 |
Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trial | 1984 |
Adjuvant therapy of breast cancer: a Southwest Oncology Group experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1984 |
Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1984 |
Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Clinical Trial | 1984 |
Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Chlorambucil; Combined | 1983 |
Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Admi | 1981 |
Adjuvant chemotherapy for breast cancer.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do | 1981 |
Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: a sequential trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Adminis | 1981 |
Chemoendocrine therapy in advanced breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide | 1981 |
Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr | 1980 |
Adjuvant chemotherapy of breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Mastecto | 1981 |
A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr | 1981 |
[The results of 5 years of ancillary chemotherapy of carcinoma of the breast (author's transl)].
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Flu | 1981 |
The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
Topics: Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Dr | 1981 |
Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An EORTC trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubic | 1980 |
CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Femal | 1980 |
Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
Topics: Aged; Amenorrhea; Axilla; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy | 1981 |
Adjuvant chemoimmunotherapy with LMF plus BCG in node-negative and node-positive breast cancer - intermediate report at 4 years.
Topics: Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorou | 1982 |
Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Dr | 1982 |
Occasional notes. The management of early breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cast | 1982 |
Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Flu | 1982 |
[Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as T | 1982 |
Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone
Topics: Adrenalectomy; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Th | 1982 |
Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluorouracil alone in high-risk breast cancer. A Western Cancer Study Group Project.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studi | 1981 |
Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamid | 1995 |
Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Combi | 1995 |
The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1993 |
An intensive sequenced adjuvant chemotherapy regimen for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1993 |
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosp | 1993 |
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
Topics: Adult; Aged; Analysis of Variance; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dieth | 1996 |
Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1997 |
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 1995 |
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1995 |
Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1999 |
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 2001 |
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2002 |
Randomized sequential hormonal therapy vs adrenalectomy for metastatic breast carcinoma.
Topics: Adrenalectomy; Adult; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Diet | 1977 |
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
Topics: Amenorrhea; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1977 |
Combined chemo- and hormonal therapy in advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as Topic; Cycloph | 1977 |
Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients. Intermediate report of a randomized trial in 242 patients.
Topics: Administration, Oral; Aged; BCG Vaccine; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; F | 1978 |
[Combined drug treatment of far-advanced forms of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Dru | 1978 |
Pilot study on adjuvant chemotherapy and hormonal therapy for irradiated inoperable breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Dr | 1978 |
Adjuvant therapy of stage II, III breast cancer.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do | 1978 |
Levamisole: as adjuvant to cyclic chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do | 1978 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 1992 |
Chemotherapy versus observation in high-risk node-negative breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1992 |
NSABP trials of adjuvant chemotherapy for breast cancer. A further look at the evidence.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, | 1991 |
Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com | 1991 |
Systemic adjuvant therapy in women with resected node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1991 |
Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo | 1991 |
Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; | 1990 |
Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Evaluation | 1990 |
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1991 |
Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; D | 1990 |
Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administrat | 1990 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1990 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fluorour | 1990 |
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1990 |
Adjuvant chemotherapy for node-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Combined Modality Th | 1989 |
How to improve adjuvant treatment results in postmenopausal patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; | 1989 |
Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1989 |
Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1989 |
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
Adjuvant chemotherapy (CMF) for stage III breast cancer: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
The Milan experience with adjuvant chemotherapy in premenopausal breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
Scottish adjuvant breast cancer trials: results in pre-menopausal patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1989 |
Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aziridines; Breast Neoplasms; Combined Modality Ther | 1989 |
Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; C | 1989 |
A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cy | 1986 |
Mechanism of action of adjuvant chemotherapy in early breast cancer.
Topics: Adult; Age Factors; Aged; Amenorrhea; Breast Neoplasms; Clinical Trials as Topic; Combined Modality | 1986 |
Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Moda | 1988 |
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1988 |
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1989 |
Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comb | 1988 |
Increasing the response rate to cytotoxic chemotherapy by endocrine means.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1985 |
Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Co | 1988 |
Performance of general hospitals in delivering adjuvant chemotherapy to breast cancer patients. G.I.V.I.O. (Interdisciplinary Group for Cancer Care Evaluation), Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Delivery of Heal | 1988 |
Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; C | 1988 |
Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality Therapy; | 1987 |
Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1988 |
Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1988 |
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1987 |
Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 1988 |
Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1986 |
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1986 |
[Prospective randomized study of the efficacy of adjuvant hormone therapy in patients with breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1986 |
Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1987 |
Age as a prognostic factor in recurrent breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1986 |
A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; C | 1986 |
The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1985 |
Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1985 |
Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1985 |
Adjuvant chemotherapy for breast cancer. Implications of clinical trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1985 |
Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
Adjuvant systemic therapy for resectable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1985 |
A randomized controlled trial of prophylactic cytotoxic chemotherapy in potentially curable breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clin | 1985 |
Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1985 |
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 1985 |
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1985 |
Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1985 |
A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1985 |
Hormono-chemotherapy in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1985 |
Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cy | 1985 |
Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as To | 1985 |
Adjuvant treatment in operable breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cy | 1985 |
Adjuvant tamoxifen treatment in postmenopausal patients with operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1985 |
Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.
Topics: Adult; Aged; Axilla; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouraci | 1968 |
Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Follow-Up Studies; Humans; Mastect | 1969 |
88 other studies available for fluorouracil and Menopause
| Article | Year |
|---|---|
Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2014 |
HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2014 |
Thymidylate synthase gene polymorphisms effecting 5-FU response in breast cancer patients.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Enh | 2010 |
Mitoxantrone-cyclophosphamide-fluorouracil-combination chemotherapy in metastatic breast cancer. 3-Year-follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1989 |
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2007 |
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2008 |
Adjuvant chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Co | 1983 |
Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamid | 1984 |
Relationship between estrogen receptors and CMF adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1984 |
[Cytostatic therapy in metastatic breast cancer].
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 1984 |
Ludwig Breast Cancer trials LBCS III and IV: adjuvant endocrine treatment in postmenopausal patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Castration; Combined Modalit | 1984 |
CMF adjuvant programs at the Milan Cancer Institute.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1984 |
[Sequential combination chemotherapy in metastatic cancer of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1984 |
[Correlations between PRL and 17-beta-E in human breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Estradiol | 1984 |
Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients.
Topics: Adrenal Glands; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1983 |
Adjuvant chemotherapy (CMF) for breast carcinoma. Patient's compliance and total dose achieved.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1983 |
Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 1983 |
The effect of postoperative radiotherapy on the feasibility of optimal dose adjuvant CMF chemotherapy in stage II breast carcinoma.
Topics: Actuarial Analysis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marr | 1983 |
[Bone scintigraphy in mastectomized patients with and without chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Breast Neoplasms; Cyclo | 1983 |
[Breast neoplasms. Progress by means of adjuvant chemotherapy?].
Topics: Age Factors; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Ly | 1980 |
Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study.
Topics: Aged; Breast Neoplasms; Chlorambucil; Drug Administration Schedule; Drug Evaluation; Drug Therapy, C | 1983 |
Effect of time and therapy on the hormone receptor status of breast carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1982 |
Brain metastases in breast cancer patients receiving adjuvant chemotherapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Com | 1982 |
Response to oophorectomy after tamoxifen failure in a premenopausal patient.
Topics: Adult; Breast Neoplasms; Castration; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorourac | 1982 |
[Results of, and indications for adjuvant chemotherapy in breast cancer].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1981 |
[Adjuvant chemotherapy in breast neoplasms. Clinical and immunologic results].
Topics: Adult; Aged; Breast Neoplasms; Concanavalin A; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph | 1980 |
[Adjuvant chemotherapy of breast neoplasms. Review of the up-to-date results of various studies including the Heidelberg study].
Topics: Adult; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Evaluation Studies as Topic; Female; Fluoro | 1980 |
Dose-response effect of adjuvant chemotherapy in breast cancer.
Topics: Aged; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Sche | 1981 |
Locally advanced breast cancer: is surgery warranted following chemotherapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1995 |
Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; | 1995 |
PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 1993 |
Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.
Topics: Aged; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast | 1993 |
VIII. Women's health perception and breast cancer: issues of fertility, hormone substitution, and cancer prevention.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1996 |
[Combined breast-preserving surgery, chemotherapy and radiotherapy in the treatment of breast carcinoma. Effect of the interval between surgery and the beginning of radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
Breast conservation after induction chemotherapy for locally advanced breast cancer.
Topics: Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 1997 |
Endometrial carcinoma in the south of Israel: study of 231 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 1997 |
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Hormonal; Antineoplasti | 1995 |
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combin | 2000 |
Ovarian function in patients receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dehydroepia | 1977 |
Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer.
Topics: BCG Vaccine; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy; Female; Fluo | 1979 |
United States trials of adjuvant therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastect | 1977 |
Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dr | 1979 |
5-drug adjuvant chemotherapy for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoro | 1979 |
The effect of combination chemotherapy on ovarian, hypothalamic and pituitary function in patients with breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; F | 1979 |
Therapy of primary breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Fluorouracil; Humans; Lymphatic Metasta | 1977 |
Current overview of EORTC clinical trials with tamoxifen.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combina | 1976 |
Combination chemotherapy for disseminated carcinoma of the breast.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Com | 1975 |
Combination chemotherapy in metastatic carcinoma of the breast. Results with a three-drug combination.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Ethylnit | 1975 |
Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 1992 |
Chemotherapy-induced amenorrhea and other clinical and pathological parameters in the prognosis of breast cancer patients.
Topics: Adult; Amenorrhea; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1992 |
Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
Topics: Adult; Aged; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin | 1992 |
[Platelet aggregation during adjuvant chemotherapy with CMF].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1991 |
Comparison of long-term survival of 1986 consecutive patients with breast cancer treated at the National Cancer Institute of Milano, Italy (1971 to 1972 and 1977 to 1978).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noni | 1991 |
Preoperative chemotherapy in primarily inoperable cancer of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1991 |
Studies on the changes in plasma lipids and lipoproteins in CMF treated breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Cholesterol; Cisplati | 1991 |
Adjuvant oophorectomy versus CMF for premenopausal, node-positive, hormone receptor positive patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1991 |
Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorou | 1991 |
Preoperative multimodal therapy for locally advanced non-inflammatory breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cobalt Radioisotopes; Combined Mod | 1991 |
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxor | 1990 |
Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1989 |
Clinical trials referral resource. Adjuvant therapy of breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; | 1989 |
Endocrine effects of adjuvant chemotherapy in premenopausal women: suggestions for the future.
Topics: Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Ther | 1989 |
Critical review of adjuvant therapy in premenopausal patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre- and postmenopausal breast cancer.
Topics: Adrenal Cortex; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chrom | 1985 |
Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxor | 1988 |
Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; DNA, Neopl | 1988 |
The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Do | 1988 |
Chemoresistance is not a cause of the apparent failure of adjuvant chemotherapy in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Resistance; Fe | 1988 |
Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1988 |
Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Fluoroura | 1988 |
Ovarian function and adjuvant chemotherapy for early breast cancer.
Topics: Adult; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Co | 1987 |
Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamid | 1986 |
Megestrol acetate therapy for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; | 1985 |
Case 6-1985: progressive pneumonitis after chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1985 |
Chemohormonal therapy and endocrine function in breast cancer patients.
Topics: Adult; Amenorrhea; Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 1985 |
Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neopla | 1985 |
Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1985 |
Rationale for combining chemotherapy and hormonal therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1985 |
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1986 |
Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphami | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
Current concepts in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Adult; Androgens; Breast Neoplasms; Castration; Estrogens; Female; Fluorouracil; Huma | 1972 |
[FSH and steroid hormone excretion in breast cancer during chemotherapy].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Breast Neoplasms; Cyclophosphamide; Estrogens; Female; F | 1972 |
An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast.
Topics: Administration, Oral; Adult; Aged; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Drug Therap | 1974 |
Cyclical combination chemotherapy for advanced breast carcinoma.
Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos | 1974 |
Therapeutic implications from a mathematical model characterizing the course of breast cancer.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mastectomy; | 1969 |
[Comparative evaluation of thiphosphamide, cyclophosphane, methotrexate and 5-fluorouracil in the treatment of breast cancer].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Menopause; Menstruati | 1971 |